,

Macitentan improves immune response by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1

,

FDA-approaved drugs targeting an ETA elicit antitumor immune response along with immune checkpoint therapy by inhibiting exsomal PD-L1

,

IL2 induces anticancer immune response by regulating sEV secretion and PD-L1 espression in cancer cells

,

FDA-approved drugs targeting an ETA inhibits exosome secretion for potential cancer treatment

,

FDA-approved drugs targeting an ETA elicit antitumor immune response along with immune checkpoint therapy by inhibiting exosomal PD-L1